ESOU 2022

REVIEW UroToday

Viewing 1-20 of 21 articles

ESOU 2022: SABR for Kidney Cancer. Still Experimental?

ESOU 2022: Liquid Biomarkers in Advanced Kidney Cancer

ESOU 2022: Future Directions of Systemic Treatment for mRCC: What Can We Expect in the Next 5 Years?

ESOU 2022: State-of-the-Art Lecture – The Changing Face of Advanced Prostate Cancer and Implications for Evidenced Based Medicine

ESOU 2022: The Evolving Treatment Landscape and Clinical Trial Overview of Penile Squamous Cell Carcinoma

ESOU 2022: Complications and Management of Robotic Assisted Partial Nephrectomy

ESOU 2022: Neoadjuvant Treatments before Radical Prostatectomy for High-Risk Prostate Cancer: Developments and Challenges

ESOU 2022: Robotic Transperitoneal and Retroperitoneal Approach: When and How

ESOU 2022: Functional Results Following Partial Nephrectomy; Acute Kidney Injury and Chronic Kidney Disease Consequences: A New Perspective

ESOU 2022: Indication and Results of Robotic Partial Nephrectomy for T1/T2 Tumours

ESOU 2022: Management of Indeterminate Testicular Masses

ESOU 2022: Follow-Up of Stage I and II Seminoma: What’s New?

ESOU 2022: Stage II Seminoma: What Is the Role for Retroperitoneal Lymph Node Dissection?

ESOU 2022: An Update on Thromboprophylaxis During Chemotherapy for Metastatic Germ Cell Tumours

ESOU 2022: En Bloc Resection in Non-muscle Invasive Bladder Cancer: Where Do We Stand?

ESOU 2022: New Tools for the Conservative Management of Upper Tract Urothelial Carcinoma

ESOU 2022: How MRI Changed the Bladder Cancer Pathway: New Evidence

ESOU 2022: Early Cystectomy: Selection of the Best Candidate and Outcomes. BRAVO Trial Implications for Patient Selection

ESOU 2022: 3D Augmented Reality in Robotic Assisted Partial Nephrectomy – What’s Next?

ESOU 2022: Precision Medicine – Artificial Intelligence for Kidney Cancer Diagnosis

1
2